Bicara Therapeutics (NASDAQ:BCAX) Insider David Raben Sells 22,000 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) insider David Raben sold 22,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $18.45, for a total value of $405,900.00. Following the transaction, the insider directly owned 35,497 shares of the company’s stock, valued at $654,919.65. This represents a 38.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Bicara Therapeutics Trading Down 2.6%

Shares of Bicara Therapeutics stock opened at $17.78 on Friday. Bicara Therapeutics Inc. has a 12 month low of $7.80 and a 12 month high of $28.09. The business has a fifty day simple moving average of $12.51 and a two-hundred day simple moving average of $11.87. The firm has a market capitalization of $970.97 million and a P/E ratio of -5.61.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.04. Analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCAX has been the topic of several recent analyst reports. Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. HC Wainwright dropped their price objective on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicara Therapeutics in a research note on Saturday, September 27th. Finally, Piper Sandler started coverage on Bicara Therapeutics in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.86.

Institutional Trading of Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System bought a new stake in Bicara Therapeutics during the 4th quarter valued at $25,000. CWM LLC bought a new stake in Bicara Therapeutics during the 1st quarter valued at $29,000. Legal & General Group Plc boosted its position in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Bicara Therapeutics in the 1st quarter worth $52,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.